Company intelligence / Profile preview

ImQuest Life Sciences

Frederick, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Prior to its acquisition, ImQuest Life Sciences developed and evaluated preclinical drug candidates for infectious diseases (notably HIV), cancer, and inflammation. Their pipeline included small molecules and biologics primarily focused on antiviral and anti-cancer activity, including identification of compositions leveraging the STAT-200 platform for immune modulation. Some clinical programs reached IND-enabling studies; IQP-0410 for HIV reached IND application stage, while others such as NSC-665353 were discontinued.

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: Small moleculeBiologicVaccineNatural product
Industry: Biotech

Partnerships

MolSoft

Beyond the preview

Go deeper on ImQuest Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImQuest Life Sciences.

Explore the full profile